Well Referenced

Tag: disease-free survival

Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis

This 2010 study investigated the expression of matrix metalloproteinase 9 (MMP-9) in prostate cancer tissues and its association with Gleason score and disease prognosis. Immunohistochemical analysis of 187 pT3NxM0 prostate cancer samples revealed that high MMP-9 expression (>50% of cancer cells) was significantly associated with higher Gleason scores (P =

Read More »
June 26, 2025 No Comments

No difference in disease-free survival after oral cancer resection with close tumor margins in patients with and without postoperative radiotherapy

This 2018 retrospective cohort study analyzed outcomes in 418 patients with oral or oropharyngeal squamous cell carcinoma based on margin status post-resection: clear (>5 mm), close (1–5 mm), and positive (≤1 mm). The 5-year disease-free survival (DFS) for patients with clear and close margins was not significantly different (79.3% vs.

Read More »
June 26, 2025 No Comments

Systematic Evaluation of the Clinical Effects of Supportive Mistletoe Treatment Within Chemo- And/or Radiotherapy Protocols and Long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study

​A multicenter, controlled, observational cohort study evaluated the effects of supportive mistletoe extract (Iscador) treatment in patients with nonmetastatic colorectal carcinoma undergoing adjuvant therapy. The study involved 804 patients (429 receiving Iscador and 375 controls) across 26 centers, with a median follow-up of 58 months for the Iscador group and

Read More »
June 26, 2025 No Comments

The Effect of an Adjuvant Mistletoe Treatment Programme in Resected Head and Neck Cancer Patients: A Randomised Controlled Clinical Trial

​A randomized controlled trial involving 477 patients with resected head and neck squamous cell carcinoma assessed the efficacy of an adjuvant mistletoe extract treatment. The study found no significant improvement in disease-free survival, with a hazard ratio of 0.959 (95% CI 0.725–1.268), and no differences in immune response or quality

Read More »
June 26, 2025 No Comments

Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland

This multicenter, comparative cohort study evaluated the long-term use of fermented European mistletoe extract (Iscador) as an adjuvant therapy in patients with intermediate- to high-risk malignant melanoma (UICC/AJCC stage II-III). The treatment group, receiving subcutaneous mistletoe 2-3 times per week, showed improved tumor-related survival, better disease-free survival, and fewer brain

Read More »
June 26, 2025 No Comments